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A b s t r a c t
The expression of protein RCAS1 (receptor-binding cancer antigen expressed on SiSo cells), possibly involved in the 
mechanisms of evasion of immune surveillance by tumours, has been studied in brain astrocytomas grade III and IV 
and in metastatic carcinomas to the brain by means of double immunofluorescence with antibodies against RCAS1 and 
respectively anti-GFAP (astroglia) or CD68 or CD74 (macrophages/microglia). Expression of RCAS1 has been reported 
in many types of carcinomas and in some normal cells, including bone marrow macrophages. Nakabayashi and co-
workers recently reported expression of RCAS1 in gliomas. So far no attention has been paid to expression of RCAS1 
in non-neoplastic cellular elements of tumours such as macrophages and to the expression of RCAS1 in metastatic 
carcinomas. We found expression of RCAS1 co-localizing with GFAP+ cells of gliomas and with CD68 and CD74 in 
large macrophages infiltrating metastatic and primary tumours and sometimes in cells which had morphological 
characteristics of microglia. Moreover, sometimes strong RCAS1 positivity has been found in metastatic carcinomas. 
Whether expression of RCAS1 in macrophages accompanying brain tumours is of any importance it is not possible 
to ascertain at present. However, when elucidating the possible role of RCAS1 in tumour biology, it seems to be 
necessary to include its presence not only in neoplastic cells. 
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Introduction
Malignant tumours at least at some stage of ma-
lignant transformation are able to evade immune su-
rveillance of the host. They possibly do it in different 
ways but probably the most important mechanisms 
of their defence against the immune response are the 
factors either secreted or bound to the tumour mem-
brane that may actively “silence” the immune cells, 
for instance by induction of their apoptosis. These 
factors may include protein RCAS1 – a membrane 
molecule which may induce apoptotic cell death of 
lymphocytes including T, B and NK cells [12]. RCAS1 
(denoting “receptor binding cancer antigen expres-
sed on SiSo cells”) for the first time was described 
by Sonoda as a “novel tumour associated antigen” 
discovered in cell line SiSo derived from adenocar-
cinoma of uterine cervix [16,21]. The SiSo cell line 
had been established by Sonoda and co-workers in 
1995 [16]. RCAS1 is recognized by monoclonal antibo-
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dy MoAb22-1, which reacted with SiSo cells. Sonoda 
and co-workers showed that antigen recognized by 
antibody MoAb22-1 is present on the surface of ova-
rian as well as uterine carcinoma cells and that the 
level of expression is especially marked in invasive 
cancer [16,17]. Apart from uterine cancers expression 
of RCAS1 has been reported in many other tumours 
such as pulmonary, oesophageal, and pancreatic can-
cers [3,4,11,18,25]. It is possible that RCAS1 when pre-
sent on the surface of different neoplastic cells may 
be engaged in the “escape” of the tumour from the 
immunological surveillance of the host, acting via the 
receptor on T lymphocytes [19]. Apart from tumours, 
a possible role of RCAS1 in immunological processes 
associated with pregnancy has been reported [23,24]. 
Nakabayashi and co-workers also reported expres-
sion of RCAS1 in gliomas, suggesting its role in the 
mechanism of immune escape by these tumours [10]. 
There also exists a report of Chinese authors but ava-
ilable in English only in abstract [15]. As already men-
tioned, strong expression of RCAS1 has been found 
in many malignant tumours, especially carcinomas, 
but according to our knowledge little attention, if any, 
has been paid to metastases. The question arises 
whether the expression of RCAS1 (if present) can be 
somehow related to the immunological response of 
the host. Our preliminary study showed sometimes 
strong expression of RCAS1 (detected immunohisto-
chemically) in metastatic carcinomas of the brain 
and also in gliomas. We did not however find eviden-
ce that there is a correlation between lymphocytes 
infiltrate within the tumour and the level of RCAS1 
expression [1]. We turned our attention to the strong 
expression of RCAS1 in non-neoplastic cells, appa-
rently macrophages. The expression was apparently 
even stronger than in many neoplastic cells. Tumour-
infiltrating macrophages seem to be not only secon-
dary bystanders or just scavengers but may play an 
active role in tumour progression [13]. Here especially 
interesting is the finding that tumour-associated ma-
crophages may suppress adaptive immunity inducing 
apoptosis of CD8+ T cells and promote angiogenesis 
[7,14]. In this context it seems noteworthy to recol-
lect the already mentioned putative role of RCAS1 in 
evasion of the immune reaction by tumours and also 
the recent report of Sonoda et al., who have found 
evidence of a role of RCAS1 in regulation of angioge-
nesis in tumours [20]. The aim of this study was to 
find more convincing evidence that RCAS1 co-locali-
zes with macrophages using double immunofluore-
scence with two antibodies: against RCAS1 and CD68 
(a transmembrane glycoprotein, marker of macro-
phages). Moreover, we wanted to check whether the-
re exists co-localization of RCAS1 with CD74 antigen, 
which is primarily expressed on antigen-presenting 
cells, including B cells, monocytes/macrophages and 
dendritic/microglial cells (and is called “invariant po-
lypeptide of major histocompatibility complex, class 
II antigen-associated”), and plays a role in chapero-
ning MHC class II molecules from the endoplasmic 
reticulum to the cell surface [22]. 
Material and Methods 
Twenty cases of primary (gliomas: 6 grade III and 
14 grade IV) and 20 metastatic (all including carci-
nomas) human brain tumours diagnosed neuropa-
thologically in the Department of Neuropathology 
were investigated. The protocol of indirect double 
immunostaining was employed to demonstrate the 
expression of RCAS1 in cells of microglia and macro-
phage immunophenotype (CD68 and CD74). Paraffin 
sections were dewaxed and rehydrated. For antigen 
unmasking the slides were microwaved in citrate 
buffer 2 × 5 min and then they were pre-incuba-
ted in antibody diluent (DAKO, Glostrup, Denmark, 
# S0809) for 30 min to reduce non-specific binding 
and to increase penetration of the antibodies. For 
simultaneous demonstration of two antigens in the 
combinations RCAS1/CD68, RCAS1/CD74, and RCAS1/
GFAP, a double immunofluorescence procedure using 
primary antibodies raised in different species (RCAS1 
– mouse monoclonal; CD68, CD74, and GFAP – rabbit 
polyclonal) was applied. The slides were incubated 
overnight in humid chambers at room temperature 
with the mixtures of two primary antibodies: (RCAS1, 
clone 22-1-1, Medical and Biological Laboratories, 
Naka-ku Nagoya, Japan, # D060-3, diluted 1 : 1000; 
CD68, Santa Cruz, Santa Cruz, CA, # sc-9139, diluted 
1 : 100; CD74, Sigma, St. Louis, MO, # HPA010592, 
diluted 1:250, GFAP Sigma St. Louis, #G9269 diluted 
1 : 100). After rinsing in PBS slides were incubated 
with secondary antisera: (1) Cy3-conjugated goat 
anti-mouse IgG (# 115-165-146, diluted 1 : 800), (2) 
Cy2-conjugated goat anti-rabbit IgG (# 111-225-144, 
diluted 1 : 200; both from Jackson ImmunoResearch, 
West Grove, PA). Primary and secondary antibodies 
were diluted in the same diluent as used for pre-in-
cubation. After a final rinse in PBS the slides were 
mounted in glycerin/PBS medium. 
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Microscopy examination. A Nikon Eclipse 80i epi-
fluorescence microscope equipped with mercuric 
burner and filter sets G-2A and B-2 E/C for detection 
of Cy3 (red) and Cy2 (green) fluorescence respective-
ly was used to examine the immunostaining. Images 
were recorded using a Nikon DS-Fil digital camera 
and stored as TIFF files.
Results
In all investigated tumours RCAS1 antibody “sta-
ined” large macrophages in which it co-localized with 
CD68 and CD74. The largest CD68+ macrophages 
with ample, coarsely granular cytoplasm, apparently 
representing so-called “gitter cells”, were almost uni-
formly strongly RCAS1 positive both in carcinomas 
and gliomas (Figs. 1 and 6 respectively). Large CD68+ 
macrophages were also CD74 positive (Fig. 5). Howe-
ver, this is the conclusion resulting from comparison 
of corresponding places on slides from the same 
specimen, since in the double immunofluorescence 
CD68 and CD74 antibodies were “paired” with RCAS1, 
not with each other. Only rarely RCAS1 co-localized 
with CD68 in medium or small cells (Fig. 4) and as 
Fig. 1. RCAS1 (red), CD68 (green). CD68 co-locali-
zes with RCAS1 in large macrophages (arrow), so-
called “gitter cells”, forming clusters in the vicini-
ty of carcinoma cells (asterisk). Bar = 20 µm. 
Fig. 2. RCAS1 (red), CD74 (green). CD74 positive, 
RCAS1 negative reactive microglia around vessel 
(asterisk). Case of glioblastoma multiforme. Bar 
= 20 µm. 
Fig. 3. RCAS1 (red), CD74 (green). Unspecific fluore-
scence in red channel of lipofuscin in neuron (ar-
row). A few small CD74+ cells probably represent 
(quiescent) microglia in the cerebral cortex in the 
vicinity of glioblastoma infiltration. Bar = 20 µm.
Fig. 4. RCAS1 (red), CD68 (green). RCAS1 co-loca-
lizes with CD68 only in some small size CD68+ 
macrophages (arrows) dispersed among carci-
noma cells (asterisks). Bar = 20 µm. 
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a result, the large macrophages were practically the 
only CD68 or CD74 positive cells co-localizing with 
RCAS1. Other cells positive for RCAS1 were carcino-
ma (Fig. 7) and glioma cells, the latter co-localizing 
with GFAP – a marker of astroglia (Fig. 8). In cortical 
areas not infiltrated by tumour, large neurons sho-
wing unspecific fluorescence of lipofuscin could be 
mistaken for “large macrophages” (Fig. 3). The issue 
of unspecific autofluorescence is crucial for the pro-
per interpretation of results of immunofluorescence 
Fig. 5. RCAS1 (red), CD74 (green). Large macro-
phages in the cluster inside metastasis of carci-
noma are CD74 positive (arrow). Large atypical 
carcinoma cell is also CD74+ but RCAS1- (arrow- 
head). Bar = 20 µm.
Fig. 6. RCAS1 (red), CD68 (green). RCAS1 co-loca-
lizes with CD68 in large macrophages (arrow) but 
some smaller CD68+ macrophages (arrowhead) 
either do not express RCAS1 or the expression is 
remarkably weaker than that of CD68. Case of 
glioblastoma. Bar = 20 µm.
and not only neurons may show this “nasty” featu-
re. At some point we suspected that especially large 
macrophages (“gitter cells”) may also autofluoresce. 
Therefore we compared the specimens with immu-
nofluorescence with the “control” slides of the same 
tumours processed identically except for the primary 
and secondary antibodies. Next, digital photographs 
of the corresponding places on control and “fully pro-
cessed” slides were taken, with precisely the same 
Fig. 7. RCAS1 (red), GFAP (green). Relatively 
strong expression of RCAS1 in large clusters of 
carcinoma cells (yellow asterisk) and reactive 
astrocytic gliosis (red asterisk). Bar = 20 µm.
Fig. 8. RCAS1 (red), GFAP (green). RCAS1 in the 
form of tiny grains and specks (arrowhead) co-
localizes with GFAP. A considerable part of the 
area is occupied by endothelial proliferation 
(asterisk), negative for GFAP and with only gen-
tle background staining and with unspecific au-
tofluorescence of erythrocytes (arrow). Case of 
glioblastoma. Bar = 20 µm.
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camera settings (time of exposure, etc.). Evidently 
large macrophages which exhibited some autoflu-
orescence unequivocally presented a stronger signal 
in slides where full immunofluorescence was perfor-
med. Macrophages CD68+ were much more numero-
us in metastatic tumours than in gliomas. CD68- but 
Fig. 9. RCAS1 (red), CD74 (green). Small or me-
dium size CD74+ cells gathering in an area 
between clusters of carcinoma cells showing 
some positivity for RCAS1 (asterisks). One of the 
CD74+ cells apparently is also RCAS1+ (arrow). 
Noteworthy is an elongated “rod cell” (arrow- 
head). Bar = 20 µm. 
Fig. 10. RCAS1 (red), CD74 (green). Strongly 
CD74+ small round cells devoid of any processes 
corresponding to lymphocytes infiltrating tu-
mour (carcinoma). The cells are localized in the 
space between a markedly dilated blood vessel 
(asterisk) and a compacted layer of carcinoma 
cells (one of them notably showing RCAS1 posi-
tivity in cytoplasm – arrow). Bar = 20 µm.
Fig. 11. RCAS1 (red), CD74 (green). Different mor-
phological types of CD74+, some of them with 
characteristically elongated, rod-like morphology 
(arrowhead). None of the CD74+ cells is RCAS1+. 
Case of glioma gr. III. Bar = 20 µm.
Fig. 12. RCAS1 (red), CD74 (green). CD74 co-lo-
calizes with RCAS1 in some carcinoma cells (ar-
row). Bar = 20 µm.
CD74+ and supposedly microglia-derived cells were 
typically small or medium size. They were more or 
less uniformly scattered within gliomas and brain 
tissue free of neoplasm. In metastatic cancers they 
usually gathered between clusters of carcinoma cells 
(Fig. 9). The population of CD74+ cells was morpho-
logically heterogeneous. Apart from the above-men-
tioned difference in size, there were marked diffe-
rences in their shape. The smallest, round or oval 
shape cells with very scarce cytoplasm and apparen-
tly devoid of processes (Fig. 10), probably represent 
lymphocytes, especially B cells, since these cells are 
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known to express CD74 [27]. Some have processes 
but they are very slender. Still others also had more 
conspicuous cytoplasm and usually thicker proces-
ses (Fig. 2). Moreover, there was a separate subpopu-
lation of CD74+ cells that showed characteristically 
elongated, rod-like morphology (Fig. 11). Different 
morphological phenotypes of CD74+ cells described 
above represent almost certainly at least different 
activation stages of microglia and some also diffe-
rent types of cells (B cells). Numerous carcinoma cells 
also showed CD74 immunopositivity, sometimes in 
larger clusters of cells (Fig. 12).
Discussion 
Our investigations indicate that at least some 
macrophages accompanying/infiltrating brain tumo-
urs express protein RCAS1. What is the role of acti-
vated microglia/macrophages present within and in 
the vicinity of brain tumour, whether they are merely 
scavengers or play some more important function in 
the host-tumour relationship, has not as yet been 
definitely elucidated. The cross-talk between ma-
crophages and tumour cells may be suppressing but 
also promoting tumour growth [13]. One cannot exc-
lude either possibility. Stimulated microglial cells are 
transformed functionally and morphologically from 
the “quiescent”, resting state of cells with delicate, 
slender processes to the activated phase of rami-
fied, ameboid, and rod cells [6,8]. When activated, 
they become enlarged with marked cytoplasm and 
coarser but rather shorter and less numerous pro-
cesses. The end stage of transformation of microglia 
represents phagocyting macrophages (sometimes 
called “gitter cells”). Expression of RCAS1 by tumo-
ur-associated macrophages in the brain, to our best 
knowledge has not been reported so far; however, 
RCAS1 expression in macrophages elsewhere, espe-
cially in bone marrow, was reported [9]. If RCAS1 pro-
tein is truly involved in the evasion of immune surve-
illance by tumours as suggested in several reports, 
then the presence of RCAS1 in large macrophages 
could indicate the possibility that macrophages may 
take part in the mechanism of such evasion. The fact 
is that the large macrophages show especially strong 
RCAS1 positivity. The strong signal of expression of 
RCAS1 in macrophages could be matched only by the 
one which was observed in some carcinoma cells. As 
a result, one cannot exclude that macrophages 
may be involved in putative RCAS1-dependent me-
chanisms of immune evasion. Numerous apparen-
tly microglial cells at different stages of activation 
(though RCAS1 negative) including elongated “rod 
cells” showed strong positivity for CD74 (Figs. 2, 11). 
CD74 blocks the peptide-binding site of MHC class II 
molecules during its transfer from the endoplasmic 
reticulum to the cell surface [2]. Probably CD74 also 
plays a role in signal transduction since it mediates 
high-affinity binding of the pro-inflammatory cytoki-
ne macrophage migration inhibitory factor (MIF) [5]. 
Regarding the well-known fact that microglia express 
MHC class II antigens, one may justifiably speculate 
that CD74 may be of great importance for these cells. 
However, CD74 expression does not always correlate 
with that of class II molecules, and also not all acti-
vated microglia are MHC class II positive [26,27].
Conclusions
Tumour-associated microglia/macrophages ex- 
press RCAS1 but it is limited to relatively large and 
the largest macrophages. Quiescent or reactive mi-
croglial cells are apparently RCAS1-negative. Whether 
expression of RCAS1 in macrophages accompanying 
brain tumours is of any importance is not possible 
to ascertain at present. However, when elucidating 
the possible role of RCAS1 in tumour biology it seems 
to be necessary to include its expression not only in 
neoplastic cells.
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